Brief: Bivictrix Therapeutics Announces Positive Final Data In Preclinical Efficacy Study
17/07/2023 07:49
July 17 (Reuters) - BiVictriX Therapeutics PLC BVX.L :
* BIVICTRIX THERAPCTS. - POSITIVE FINAL DATA IN PRECLINICAL
EFFICACY STUDY
* BIVICTRIX-AT DAY 28, BVX001 INDUCED HIGHLY STATISTICALLY
SIGNIFICANT TUMOUR REGRESSIONS OF 97% IN A MURINE EFFICACY
STUDY OF ACUTE MYELOID LEUKAEMIA
* BIVICTRIX THERAPEUTICS PLC - UNITED STATES PATENT AND
TRADEMARK
OFFICE ISSUES A NOTICE OF ALLOWANCE FOR AN INITIAL BROAD PATENT
FOR BVX001 IN US
Source text for Eikon: ID:nRSQ1461Ga
Further company coverage: BVX.L
((Reuters.Briefs@thomsonreuters.com;))